Login / Signup

Botulinum Toxin Type A for the Treatment of Auriculotemporal Neuralgia-A Case Series.

Yan TereshkoEnrico BelgradoChristian LettieriGian Luigi GigliMariarosaria Valente
Published in: Toxins (2023)
Auriculotemporal neuralgia is a rare pain disorder in which anesthetic nerve blockade is usually effective but not always resolutive. Botulinum toxin type A has proven to be effective in treating neuropathic pain, and patients with auriculotemporal neuralgia could also benefit from this treatment. We described nine patients with auriculotemporal neuralgia treated with botulinum toxin type A in the territory of auriculotemporal nerve innervation. We compared the basal NRS and Penn facial pain scale scores with those obtained 1 month after BoNT/A injections. Both Penn facial pain scale (96.67 ± 24.61 vs. 45.11 ± 36.70, p 0.004; mean reduction 52.57 ± 36.50) and NRS scores (8.11 ± 1.27 vs. 4.22 ± 2.95, p 0.009; mean reduction 3.89 ± 2.52) improved significantly at one month after treatment. The mean duration of the effect of BoNT/A on pain was 95.00 ± 53.03 days and no adverse effects were reported.
Keyphrases
  • botulinum toxin
  • neuropathic pain
  • chronic pain
  • spinal cord
  • spinal cord injury
  • pain management
  • peripheral nerve
  • soft tissue
  • platelet rich plasma